MTOR and neoplasm: The resulting bioenergetic insufficiencies inhibit mammalian target of rapamycin (mTOR) activity and IFNγ production, impair EZH2 (enhancer of zeste 2 polycomb repressive complex 2 subunit) expression in T cells, and reduce the level of phosphoenolpyruvate, which is linked with a lack of activation of CD4+ tumor-infiltrating lymphocytes (61).